Chronic Hepatitis C Treated with Peginterferon alfa plus Ribavirin in Clinical Practice

2 Value at Risk and Expected Shortfall Estimation for High Dimen- sional Portfolios via Factor Copulas: an Application to Brazilian BOVESPA Stock

em vários momentos nos discursos dos entrevistados. O critério tem relação direta [3] com os espaços construídos, diretamente visível no desenho de todas as

O movimento retoma idéias de outras vanguardas (como o futurismo e o dadaísmo) e, mesmo depois de mais de quarenta anos de seu surgimento, provoca polêmica,

Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Using pegylated

The present study aimed to evaluate the association between pretreatment plasma levels of chemokines and soluble tumor necrosis factor recep- tors (sTNF-R) and the virological

The post-treatment fibrosis annual progression rate in comparison with the fibrosis stage on the pre-treatment biopsy showed a significantly higher decrease of this progression

Our data, based on a cohort of chronic hepatitis C cir- rhotic patients previously treated with interferon and ribavirin, showed a significant reduction on HCC

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin